TLD isn't something the company knows, it's something they create once they have the data from the trial. It's only a few paragraphs that summarizes the results of the trial and whether it's meeting the goals needed to gain approval. The company hasn't wanted to release TLD because it fails to answer so many questions, and shorts can target that.
The company can't really discuss the data before it's been presented somewhere for peer review, in this case they also knew how complex the trial was and that it could be far more comprehensively covered by a Journal rather than a short presentation at a conference. Don't get me wrong, I still believe a presentation could be coming just before the Journal and it could come in June, just after ASCO. Conferences insist that all information presented be new, so Journal are willing to wait to achieve both if that's what's desired by those involved.
I have no idea how close the Journal may be to being ready to publish, nor do I know if Dr. Liau submitted to ASCO for presentation. If she did, up to a certain date the Abstract could be withdrawn, until that date it would be her and the company's option. I believe that if the publication could be out in late April or later I think it would be worth waiting for ASCO in early June and get the exposure of presenting in the largest Oncology conference I know of then get the publication. If this is the choice, by late this month we might be able to tell when presentation titles are released, but if we can't be certain from the title, the Abstract's will be out in late May.
Gary
